Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Kitzing

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nature Reviews. Cancer|February 18, 2011
Nucleating actin for invasionAlexander Nürnberg, Thomas Kitzing, Robert Grosse
Clinical Pharmacology and Therapeutics|February 8, 2025
Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target EngagementIrina Kareva, Ping Hu, Vadryn Pierre, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2020
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapyMartin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
The Journal of Biological Chemistry|August 13, 2008
The Diaphanous-related Formin FHOD1 associates with ROCK1 and promotes Src-dependent plasma membrane blebbingSebastian Hannemann, Ricardo Madrid, Jana Stastna, et al.
Translational Lung Cancer Research|January 20, 2025
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNISMartin Reck, Konstantinos Syrigos, Skaidrius Miliauskas, et al.
Clinical Colorectal Cancer|October 12, 2020
Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Developmental Cell|September 23, 2008
Integrin trafficking regulated by Rab21 is necessary for cytokinesisTeijo Pellinen, Saara Tuomi, Antti Arjonen, et al.
Journal for Immunotherapy of Cancer|February 10, 2025
TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trialAung Naing, Meredith McKean, Anthony Tolcher, et al.
Nature Genetics|March 31, 2015
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesisZhen Zhao, Chi-Chao Chen, Cory D Rillahan, et al.
Genes & Development|August 17, 2014
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaChun-Hao Huang, Amaia Lujambio, Johannes Zuber, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature Reviews. Cancer|February 18, 2011
Nucleating actin for invasionAlexander Nürnberg, Thomas Kitzing, Robert Grosse
Clinical Pharmacology and Therapeutics|February 8, 2025
Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target EngagementIrina Kareva, Ping Hu, Vadryn Pierre, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2020
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapyMartin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
The Journal of Biological Chemistry|August 13, 2008
The Diaphanous-related Formin FHOD1 associates with ROCK1 and promotes Src-dependent plasma membrane blebbingSebastian Hannemann, Ricardo Madrid, Jana Stastna, et al.
Translational Lung Cancer Research|January 20, 2025
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNISMartin Reck, Konstantinos Syrigos, Skaidrius Miliauskas, et al.
Clinical Colorectal Cancer|October 12, 2020
Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Developmental Cell|September 23, 2008
Integrin trafficking regulated by Rab21 is necessary for cytokinesisTeijo Pellinen, Saara Tuomi, Antti Arjonen, et al.
Journal for Immunotherapy of Cancer|February 10, 2025
TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trialAung Naing, Meredith McKean, Anthony Tolcher, et al.
Nature Genetics|March 31, 2015
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesisZhen Zhao, Chi-Chao Chen, Cory D Rillahan, et al.
Genes & Development|August 17, 2014
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaChun-Hao Huang, Amaia Lujambio, Johannes Zuber, et al.
Pageof 2